Nanotechnology is the design and development of materials, structures, and devices with at least 1 dimension between the 1- and 100-nm-size scale. Manipulating matter at the atomic scale offers unique opportunities in material design particularly in biological interfaces. In this short review, we explore the disruptive technological opportunities that nanotechnology and microelectromechanical systems may offer in possible future stent designs along with safety issues that may surface with the use of nanoparticles in medical devices.
MoriceMCSerruysPWSousaJE. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–1780.
2.
StoneGWEllisSGCoxDA. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2002;350(3):221–231.
3.
AcharjeeSCannonCP. Duration of dual antiplatelet therapy following percutaneous coronary intervention with drug-eluting stents: a review of recent evidence. Crit Pathw Cardiol. 2010;9(4):203–206.
4.
McFaddenEPStabileERegarE. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519–1521.
5.
TakahataKDeHennisAWiseKD. Stentenna: a micromachined antenna stent for wireless monitoring of implantable microsensors. Presented at: 25th Annual International Conference of the IEEE: Engineering in Medicine and Biology Society.September 17-21, 2003; Cancun Mexico.
6.
ChowEYChlebowskiALChakrabortySChappellWJIrazoquiPP. Fully wireless implantable cardiovascular pressure monitor integrated with a medical stent. IEEE Trans Biomed Eng. 2010;57(6):1487–1496.
7.
NuxollEESiegelRA. BioMEMS devices for drug delivery. IEEE Eng Med Biol Mag. 2009;28(1):31–39.
8.
KimDHKimYSAmsdenJ. Silicon electronics on silk as a path to bioresorbable, implantable devices. Appl Phys Lett. 2009;95(13):133701–133704.
9.
SharmaSChristopoulosCKukrejaNGorogDA. Local drug delivery for percutaneous coronary intervention. Pharmacol Ther. 2011;129(3):260–266.
10.
ReedMLWuCKnellerJ. Micro-mechanical devices for intravascular drug delivery. J Pharm Sci. 1998;87(11):1387–1394.
11.
CavesJMChaikofEL. The evolving impact of microfabrication and nanotechnology on stent design. J Vasc Surg. 2006;44(6):1363–1368.
12.
ShawgoRSGraysonACRLiY. BioMEMS for drug delivery. Curr Opin Solid State Mater Sci. 2002;6(4):329–334.
13.
OnumaYOrmistonJSerruysPW. Bioresorbable scaffold technologies. Circ J. 2011;75(3):509–520.
14.
LiuYMiyoshiHNakamuraM. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007;120(12):2527–2537.
15.
UwatokuTShimokawaHAbeK. Nanoparticle technology for the prevention of restenosis after balloon injury in rats. Circ Res. 2003;92(7):e62–e69.
16.
van BeusekomHMWhelanDMHofmaSH. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol. 1998;32(4):1109–1117.
17.
WeisslederRKellyKSunEYShtatlandTJosephsonL. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005;23(11):1418–1423.
18.
JayagopalALintonMFFazioSHaseltonFR. Insights into atherosclerosis using nanotechnology. Curr Atheroscler Rep. 2010;12(3):209–215.
19.
WicklineSANeubauerAMWinterPCaruthersSLanzaG. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol. 2006;26(3):435–441.
20.
BrammerKSChoiCOhS. Antibiofouling, sustained antibiotic release by Si nanowire templates. Nano Lett. 2009;9(10):3570–3574.
21.
PolyakBFishbeinIChornyM. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A. 2008;105(2):698–703.
22.
BritoLAmijiM. Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomedicine. 2007;2(2):143–161.
23.
KipshidzeNDangasGTsapenkoM. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol. 2004;44(4):733–739.
24.
DavidDMBoyleFJ. Drug-eluting stents for coronary artery disease: a review. Med Eng Phys. 2011;33(2):148–163.
25.
InoueTSataMHikichiY. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation. 2007;115(5):553–561.
26.
KaragiozakiVCLogothetidisSDKassavetisSNGiannoglouGD. Nanomedicine for the reduction of thrombogenicity of stent coatings. Int J Nanomedicine. 2010;7(5):239–248.
27.
LoyaMCBrammerKSChoiCChenLHJinS. Plasma-induced nanopillars on bare metal coronary stent surface for enhanced endothelialization. Acta Biomater. 2010;6(12):4589–4595.
28.
ShenYWangGChenL. Investigation of surface endothelialization on biomedical nitinol (NiTi) alloy: effects of surface micropatterning combined with plasma nanocoatings. Acta Biomater. 2009;5(9):3593–3604.
29.
ParetaRAReisingABMillerTStoreyDWebsterTJ. Increased endothelial cell adhesion on plasma modified nanostructured polymeric and metallic surfaces for vascular stent applications. Biotechnol Bioeng. 2009;103(3):459–471.
30.
HaberstrohKM. Vascular nano stents. In: TJWebster, ed. Nanotechnology for the Regeneration of Soft and Hard Tissues. World Scientific Publishing; 2007:181–201.
31.
WendelinJS.Nanoparticles in biological systems. Angew Chem Int Ed Engl. 2011;50(6):1242–1258.
